跳至主要内容

MedPath Trial Home

机构资讯 AI 研究

数据来源：ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

搜索试验。追踪管线。洞察审批。由 AI 驱动的临床研究情报平台。

产品

临床试验
药物情报
全球审批
深度研究
价格方案

资源

常见问题
搜索

公司

资讯
关于我们
联系我们

法律

隐私政策
服务条款

免责声明： 本网站提供信息检索和数据分析服务。内容不构成医疗建议。适应性评估仅供参考，不能替代合格医疗专业人员的咨询。数据来源于公共注册库和监管机构；MedPath 不保证数据的完整性或准确性。请以原始资料为准。

© 2026 MedPath Trial 版权所有

服务条款隐私政策

我们重视您的隐私

我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。

Gruppo Oncologico del Nord-Ovest

首页临床试验发起方与机构Gruppo Oncologico del Nord-Ovest

Gruppo Oncologico del Nord-Ovest

CLOSED

意大利gonogroup.orgPrivate成立于: 1987-01-01

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

相关临床试验

63

11 进行中

药物批准

0

批准总数

监管机构

0

监管机构数

成立时间

1987

概览

试验阶段分布

阶段

试验数

占比

2 期

40

63.5%

3 期

13

20.6%

1 期

8

12.7%

4 期

2

3.2%

试验状态分布

进行中（未招募）

9

14.3%

已完成

11

17.5%

尚未招募

2

3.2%

招募中

30

47.6%

暂停

2

3.2%

终止

2

3.2%

Unknown

7

11.1%

相关临床试验

该机构主办的试验（63）

Study aimed at testing the activity of a course of chemo-immunotherapy with retifanlimab combined with platinum-etoposide followed by surgery in patients with operable Merkel cell carcinoma

36 名受试者

A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY Study.

108 名受试者

Pembrolizumab and olaparib in recurrent/metastatic, platinum resistant nasopharyngeal cancer. POINT study

30 名受试者

ShorTrip study - Phase II study of Short-course radiotherapy followed by consolidation chemotherapy with the Triplet FOLFOXIRI as total neoadjuvant therapy for locally advanced rectal cancer.

63 名受试者

PHASE III RANDOMIZED STUDY OF FOLFOXIRI PLUS BEVACIZUMAB AND ATEZOLIZUMAB VERSUS FOLFOXIRI PLUS BEVACIZUMAB AS FIRST-LINE TREATMENT OF UNRESECTABLE pMMR AND IMMUNOSCORE IC-HIGH METASTATIC COLORECTAL CANCER PATIENTS. The AtezoTRIBE2 Study

238 名受试者

Study on the combination of two immunotherapeutic agents as pre-surgical therapy or definitive treatment in patients with resectable gastric or gastroesophageal junction cancer with microsatellite instability.

31 名受试者

Single arm phase II study of ctDNA-guided encorafenib plus cetuximab retreatment in patients with BRAF V600E mutated mCRC. BRICKET study

16 名受试者

A single-arm phase II study of cetuximab plus platinum and taxane-based chemotherapy followed by AVElumab and Cetuximab as first-line therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients with PD-L1 combined positive score (CPS)≥1≤19: the immunotherapy sequence reversal

67 名受试者

药物批准

暂无批准数据

资讯

暂无资讯文章

本页目录

概览
相关临床试验63
药物批准
资讯

返回机构列表